Floatz logo

Valemetostat

Head and Neck Carcnimona

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Head and Neck Carcnimona cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Pembrolizumab
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Tadalafil
University of California, San Diego
Phase 2B
Gdc-0068
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Valemetostat is also rated in:

adult T-cell leukemia/lymphomaDormant
B
Indicative ·
57 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
53 / 100
View asset →
endometrial clear cell adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →